Antibody, Bioavailability and Nurses - Clinical Research Informer

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Antibody

Bioavailability

Nurses

Considerations for Neuroscience Trials with Intrathecal Delivery and Other Methods of Direct CNS Administration

XTalks

AUGUST 30, 2022

A major obstacle for CNS drug developers is the inability to target therapies to the CNS broadly (for instance, a therapy that is orally bioavailable as a pill and has difficulty crossing the blood-brain barrier) and certain CNS regions more specifically. What About Small Proteins and Antibodies Reaching Extracellular CNS Targets?

Trials

Trials Drug Delivery Drugs Gene

New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary Endpoint

The Pharma Data

DECEMBER 3, 2020

Maribavir, an orally bioavailable anti-CMV compound, is the only antiviral agent presently in Phase 3 development for the treatment of post-transplant patients with CMV in SOT or HSCT. Complement-fixing antibodies against cytomegalovirus in different parts of the world. About Maribavir. 1 VV-MED-9909_Takeda DOF.

Drugs

Drugs Medicine Trials Development

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Considerations for Neuroscience Trials with Intrathecal Delivery and Other Methods of Direct CNS Administration

New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary Endpoint

Webinars

Stay Connected